Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Free Cash Flow (2019 - 2025)

Harmony Biosciences Holdings' Free Cash Flow history spans 7 years, with the latest figure at $126.0 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 67.95% year-over-year to $126.0 million; the TTM value through Dec 2025 reached $347.9 million, up 59.09%, while the annual FY2025 figure was $347.9 million, 59.09% up from the prior year.
  • Free Cash Flow for Q4 2025 was $126.0 million at Harmony Biosciences Holdings, up from $108.7 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $126.0 million in Q4 2025 and bottomed at $12.5 million in Q1 2021.
  • The 5-year median for Free Cash Flow is $39.8 million (2021), against an average of $51.4 million.
  • The largest annual shift saw Free Cash Flow skyrocketed 273.57% in 2021 before it decreased 28.92% in 2022.
  • A 5-year view of Free Cash Flow shows it stood at $37.5 million in 2021, then fell by 28.92% to $26.7 million in 2022, then surged by 186.97% to $76.6 million in 2023, then dropped by 1.97% to $75.0 million in 2024, then skyrocketed by 67.95% to $126.0 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Free Cash Flow are $126.0 million (Q4 2025), $108.7 million (Q3 2025), and $79.3 million (Q2 2025).